Plinabulin
- Generic Name
- Plinabulin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20N4O2
- CAS Number
- 714272-27-2
- Unique Ingredient Identifier
- 986FY7F8XR
- Indication
Investigated for use/treatment in cancer/tumors (unspecified).
- Associated Conditions
- -
- Associated Therapies
- -
Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT05130827
- Locations
- 🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
- Conditions
- Clinical Stage IV Merkel Cell Carcinoma AJCC v8Advanced Bladder CarcinomaClinical Stage III Cutaneous Melanoma AJCC v8Pathologic Stage IIIA Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8Stage III Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Bladder Cancer AJCC v8Stage IV Lung Cancer AJCC v8Advanced Lung Non-Small Cell Carcinoma
- Interventions
- First Posted Date
- 2021-05-26
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT04902040
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2
- Conditions
- Interventions
- First Posted Date
- 2020-04-15
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- BeyondSpring Pharmaceuticals Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT04345900
- Locations
- 🇨🇳
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
🇺🇸Emad Ibrahim, MD, Inc., Redlands, California, United States
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Harbin, China
Plinabulin iv Solution in Prevention of TAC Induced Neutropenia
- Conditions
- Interventions
- First Posted Date
- 2020-01-14
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- BeyondSpring Pharmaceuticals Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT04227990
- Locations
- 🇨🇳
Cancer Center of Guangzhou Medical University Breast Oncology, Guangzhou, Guangzhou, China
🇨🇳Fourth Hospital of Hebei Medical University Breast cancer department, Shijiazhuang, Hebei, China
🇨🇳China-Japan Union Hospital of Jilin University Tumor department of Hematology, Changchun, Jilin, China
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-07-03
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Salma Sabbour
- Target Recruit Count
- 39
- Registration Number
- NCT03575793
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Erlanger Health System, Chattanooga, Tennessee, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
- Conditions
- Interventions
- First Posted Date
- 2017-09-27
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- BeyondSpring Pharmaceuticals Inc.
- Target Recruit Count
- 221
- Registration Number
- NCT03294577
- Locations
- 🇺🇦
Dnipropetrovsk City Multifunctional Hospital #4 Oncology Department, Dnepropetrovsk, Ukraine
🇺🇦Prykarpatskiy Regional Oncological Center, Ivano-Frankivs'k, Ukraine
🇺🇦V.T. Zaycev Institute, Kharkiv, Ukraine
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3
- Conditions
- Interventions
- First Posted Date
- 2017-04-06
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- BeyondSpring Pharmaceuticals Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT03102606
- Locations
- 🇺🇸
Stanford University School of Medicine - Cancer Institute, Stanford, California, United States
🇺🇸Hematology/Oncology of the North Shore, Skokie, Illinois, United States
🇨🇳Heilongjiang Cancer Hospital, Harbin, Heilongjiang, China
Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2019-03-04
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 5
- Registration Number
- NCT02846792
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.